- Previous Close
2.2800 - Open
2.2200 - Bid 2.2600 x --
- Ask 2.3600 x --
- Day's Range
2.1800 - 2.2200 - 52 Week Range
2.0000 - 4.9600 - Volume
600 - Avg. Volume
9 - Market Cap (intraday)
238.254M - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3400 - Earnings Date May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
www.maxcyte.comRecent News: MYE0.F
View MorePerformance Overview: MYE0.F
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYE0.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYE0.F
View MoreValuation Measures
Market Cap
237.61M
Enterprise Value
117.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.74
Price/Book (mrq)
1.28
Enterprise Value/Revenue
3.48
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-106.29%
Return on Assets (ttm)
-12.60%
Return on Equity (ttm)
-18.73%
Revenue (ttm)
38.63M
Net Income Avi to Common (ttm)
-41.05M
Diluted EPS (ttm)
-0.3400
Balance Sheet and Cash Flow
Total Cash (mrq)
154.48M
Total Debt/Equity (mrq)
8.74%
Levered Free Cash Flow (ttm)
-13.72M